NEUROPSYCHOLOGICAL TESTING UNDER THE MEDICAL BENEFIT

Policy Number: 2018T0152P  Effective Date: June 1, 2018

Table of Contents

<table>
<thead>
<tr>
<th>INSTRUCTIONS FOR USE</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>BENEFIT CONSIDERATIONS</td>
<td>1</td>
</tr>
<tr>
<td>COVERAGE RATIONALE</td>
<td>2</td>
</tr>
<tr>
<td>APPLICABLE CODES</td>
<td>3</td>
</tr>
<tr>
<td>DESCRIPTION OF SERVICES</td>
<td>3</td>
</tr>
<tr>
<td>CLINICAL EVIDENCE</td>
<td>4</td>
</tr>
<tr>
<td>U.S. FOOD AND DRUG ADMINISTRATION</td>
<td>15</td>
</tr>
<tr>
<td>CENTERS FOR MEDICARE AND MEDICAID SERVICES</td>
<td>16</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>16</td>
</tr>
<tr>
<td>POLICY HISTORY/REVISION INFORMATION</td>
<td>20</td>
</tr>
</tbody>
</table>

INSTRUCTIONS FOR USE

This Medical Policy provides assistance in interpreting UnitedHealthcare benefit plans. When deciding coverage, the member specific benefit plan document must be referenced. The terms of the member specific benefit plan document [e.g., Certificate of Coverage (COC), Schedule of Benefits (SOB), and/or Summary Plan Description (SPD)] may differ greatly from the standard benefit plan upon which this Medical Policy is based. In the event of a conflict, the member specific benefit plan document supersedes this Medical Policy. All reviewers must first identify member eligibility, any federal or state regulatory requirements, and the member specific benefit plan coverage prior to use of this Medical Policy. Other Policies and Coverage Determination Guidelines may apply. UnitedHealthcare reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

BENEFIT CONSIDERATIONS

Before using this policy, please check the member specific benefit plan document and any federal or state mandates, if applicable.

Some benefit documents within UnitedHealthcare exclude neuropsychological testing for some or all indications. The exclusions section of the member specific benefit plan document must be consulted in order to determine benefit coverage for neuropsychological testing.

Neuropsychological testing for attention-deficit/hyperactivity disorder (ADHD) is a medical benefit service when medically referred and related or secondary to a known/suspected organic-medical condition resulting from brain injury or disease process (e.g., concussion, intractable seizure disorder, cancer treatment effects). Neuropsychological testing for ADHD is a mental health benefit service when representing a developmental condition not due to specific brain injury or disease process, where there are suspected organic functional impairments.

The scope of the criteria for attention-deficit/hyperactivity disorders and developmental disorders or significant developmental delays is applicable only to neuropsychological testing that is covered by the medical benefit.

Essential Health Benefits for Individual and Small Group

For plan years beginning on or after January 1, 2014, the Affordable Care Act of 2010 (ACA) requires fully insured non-grandfathered individual and small group plans (inside and outside of Exchanges) to provide coverage for ten categories of Essential Health Benefits (“EHBs”). Large group plans (both self-funded and fully insured), and small
group ASO plans, are not subject to the requirement to offer coverage for EHBs. However, if such plans choose to provide coverage for benefits which are deemed EHBs, the ACA requires all dollar limits on those benefits to be removed on all Grandfathered and Non-Grandfathered plans. The determination of which benefits constitute EHBs is made on a state by state basis. As such, when using this policy, it is important to refer to the member specific benefit plan document to determine benefit coverage.

COVERAGE RATIONALE

Neuropsychological testing is proven and/or medically necessary for evaluating individuals with the following conditions when the result of testing will influence clinical decision making:

- Attention-deficit/hyperactivity disorder (ADHD) when all of the following are present:
  - Specific neurocognitive behavioral deficits related to ADHD need to be evaluated and test results validated by a physician.
  - Testing has been recommended by a physician and is related or secondary to a known or suspected organic-medical condition resulting from brain injury or disease process (e.g., concussion, intractable seizure disorder, cancer treatment effects, genetic disorders, inborn errors of metabolism).

The scope of these criteria is applicable only to neuropsychological testing that is covered by the medical benefit. These criteria do not apply to evaluate or determine educational interventions.

- Confirmed space-occupying brain lesion including but not limited to the following:
  - Brain abscess
  - Brain tumors
  - Arteriovenous malformations within the brain

- Dementia or symptoms of dementia such as memory impairment or memory loss (including extrapyramidal disorders such as Parkinson's disease) that is associated with a new onset or progressive memory loss and a decline in at least one of the following cognitive domains (DSM-5):
  - Complex attention
  - Executive function
  - Learning and memory
  - Language
  - Perceptual-motor
  - Social cognition

- Demyelinating disorders including multiple sclerosis

- Intellectual disability or intellectual developmental disorder when all of the following are present:
  - The intellectual disability or intellectual developmental disorder is associated with a known or suspected medical cause (e.g., traumatic brain injury, in utero toxin exposure, early seizure disorder, sickle cell disease, genetic disorders) and
  - The intellectual disability or intellectual developmental disorder meets all of the following criteria (DSM-5):
    - Deficits in intellectual function, such as reasoning, problem solving, planning, abstract thinking, judgment, academic learning, and learning from experience, confirmed by both clinical assessment and individualized, standardized intelligence testing.
    - Deficits in adaptive functioning that result in failure to meet developmental and sociocultural standards for personal independence and social responsibility. Without ongoing support, the adaptive deficits limit functioning in one or more activities of daily life, such as communication, social participation, and independent living across multiple environments, such as home, school, work and community, and
    - Onset of intellectual and adaptive deficits during the developmental period

The scope of these criteria is applicable only to neuropsychological testing that is covered by the medical benefit. These criteria do not apply to evaluate or determine educational interventions.

- Encephalopathy including acquired immunodeficiency syndrome (AIDS) encephalopathy, human immunodeficiency virus (HIV) encephalopathy, hepatic encephalopathy, Lyme disease encephalopathy including neuroborreliosis, Wernicke's encephalopathy and systemic lupus erythematosus (SLE) encephalopathy.

- Neurotoxin exposure with at least one of the following:
  - Demonstrated serum levels of neurotoxins
  - Individual with documented significant prenatal alcohol, drug, or toxin exposure

- Seizure disorder including individuals with epilepsy and individuals being considered for epilepsy surgery

- Stroke

- Traumatic brain injury (TBI): TBI is defined as a bump, blow, or jolt to the head or a penetrating head injury that disrupts the normal function of the brain. (Centers for Disease Control and Prevention). See the following website for more information: http://www.cdc.gov/TraumaticBrainInjury/index.html. (Accessed March 16, 2018)

Baseline neuropsychological testing is unproven and/or not medically necessary in asymptomatic individuals at risk for sport-related concussions or brain injuries.

There is insufficient evidence to indicate that the use of baseline neuropsychological testing in athletes or other individuals alters risk from concussion. There is insufficient evidence that baseline tests influence physician decision-making or outcomes of treatment of concussion.
Computerized neuropsychological testing is unproven and/or not medically necessary for evaluating concussions or brain injuries.
The evidence is insufficient to establish the validity and reliability of computerized tests to evaluate concussions. Prospective controlled trials are needed to demonstrate the clinical utility of these tests to detect impairment following concussion.

Neuropsychological testing is unproven and/or not medically necessary for the following diagnoses alone without other proven conditions as noted above:
- Headaches including migraine headache
- History of myocardial infarction
- Intermittent explosive disorder

There is insufficient clinical evidence to demonstrate that the use of neuropsychological testing for individuals with myocardial infarction, migraine or other headaches or intermittent explosive disorder without associated cognitive disorders can be used effectively for clinical decision making to improve patient management of those conditions.

Computerized cognitive testing including but not limited to Cognivue®, Mindstreams® Cognitive Health Assessment, and BrainCare™ is unproven and/or not medically necessary for diagnosing dementia or mild cognitive impairment.
Available clinical trials have failed to document a beneficial effect of computerized cognitive testing on long-term clinical outcomes. The evidence is insufficient to establish the validity of computerized cognitive testing compared with traditional tests for the assessment of dementia and cognitive impairment.

APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>96116</td>
<td>Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, e.g., acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities), per hour of the psychologist's or physician's time, both face-to-face time with the patient and time interpreting test results and preparing the report</td>
</tr>
<tr>
<td>96118</td>
<td>Neuropsychological testing (e.g., Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), per hour of the psychologist's or physician's time, both face-to-face time administering tests to the patient and time interpreting these test results and preparing the report</td>
</tr>
<tr>
<td>96119</td>
<td>Neuropsychological testing (e.g., Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), with qualified health care professional interpretation and report, administered by technician, per hour of technician time, face-to-face</td>
</tr>
<tr>
<td>96120</td>
<td>Neuropsychological testing (e.g., Wisconsin Card Sorting Test), administered by a computer, with qualified health care professional interpretation and report</td>
</tr>
</tbody>
</table>

CPT® is a registered trademark of the American Medical Association

DESCRIPTION OF SERVICES

Neuropsychological testing is a set of formal procedures utilizing diagnostic tests specifically focused on identifying the presence of brain damage, injury or dysfunction and any associated functional deficits. Measurement of deficits cannot be based on single test results and should always be assessed in the context of the medical and neurological examination. Neuropsychological testing is customarily associated with neurological diagnoses rather than behavioral health diagnoses.

Neuropsychological tests are administered in a variety of contexts including paper-and-pencil, computers, and visual aids. Following an initial clinical interview with a neuropsychologist, tests are strategically selected to identify specific deficits and preserved abilities. Standardized tests are then administered by a trained technician or neuropsychologist. Some tests offer multiple forms making them useful for repeated administration to the same patient, thereby
minimizing practice effects. In light of the numerous procedures available for assessment of different neurocognitive functions, test selection is based on familiarity of the examiner with certain tests, availability of appropriate normative data, ability of the patient to participate in testing, and validity of particular procedures for the specific function being measured.

Neuropsychological tests include but are not limited to the following: Boston Diagnostic Aphasia Examination (BDAE), Conners' Continuous Performance Test (CCPT), Controlled Oral Word Association Test (COWAT), Delis-Kaplan Test Battery, Freedom from Distractibility Index (FFDI) from the Wechsler Intelligence Scales, Gordon Diagnostic System (GDS), Halstead-Reitan Neuropsychological Battery, Rey Auditory Verbal Learning Test (RAVLT), Rey-Osterreith Complex Figure Test, Stroop Color and Word Test, Test of Variables of Attention (TOVA), Trail Making Tests, Wechsler Adult Intelligence Scale-Revised (WAIS-III/IV), Wide Range Assessment of Memory and Learning (WRAML), and Wisconsin Card Sorting Test (WCST). At times, neurocognitive measures are supplemented by emotional functioning and personality testing and include but are not limited to the following: Minnesota Multiphasic Personality Inventory-2 (MMPI-2)/Minnesota Multiphasic Personality Inventory-A (MMPI-A), Personality Assessment Inventory (PAI), Geriatric Rating Scale, Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Rorschach Inkblot Method.

Computerized testing for dementia and cognitive impairment including the Mindstreams® Cognitive Health Assessment (NeuroTrax® Corp.) uses computer-based assessments in an attempt to identify cognitive impairment in the elderly. The software programs give individuals various stimuli or puzzles to solve using a mouse or a keypad. The Mindstreams system automatically generates a report that details the individual’s performance in the standard cognitive domains, or areas, e.g., memory, attention, executive function, visual spatial perception, verbal skills, motor planning, and information processing. According to NeuroTrax, BrainCare™ is the current version of the original MindStreams product. Cognivue (Cerebral Assessment Systems, Inc.) is another computerized cognitive test that is intended for early detection of dementia signs. Individuals take the 10-minute test using the Cognivue mobile computer workstation to assess visuomotor coordination, perceptual processing, and memory. Cognivue is intended to help identify patients who may be in the early stages of dementia and should undergo further evaluation [Hayes, Cognivue (Cerebral Assessment Systems Inc.) for Assessment of Dementia, May 2017].

Computerized neuropsychological tests have been proposed to be used as part of the overall medical management of concussion to monitor recovery. Most computer-based cognitive assessment tools are designed to detect the speed and accuracy of attention, memory, and thinking ability. Currently available computerized tests include ImpACT (Immediate Post-Concussion Assessment and Cognitive Testing, ImpACT Applications, Inc.), ANAM (Automated Neuropsychological Assessment Metrics, the United States Army Medical Department), CogState Sport (Axon Sports, Ltd.), and HeadMinder (Headminder, Inc.). These tests are being investigated for baseline testing of asymptomatic persons and managing concussions once they occur.

Neuropsychological testing is within the scope of the provider's professional training and licensure when the provider is any of the following:

- A doctoral-level psychologist who is licensed to practice independently, and demonstrates sufficient training and experience.
- A psychometrist or psychometrician who administers and scores psychological tests under the supervision of a licensed doctoral-level psychologist, and whose services are billed by the supervising psychologist. The supervising psychologist must have face-to-face contact with the member at intake and during the feedback session and is responsible for final test interpretation, report writing and final signature of approval.
- A credentialed psychiatrist who meets the following requirements:
  - Recognized certification in neurology through the American Board of Psychiatry and Neurology;
  - Accreditation in behavioral neurology and neuropsychiatry through the American Neuropsychiatric Association;
  - State medical licensure specifically allowing for the provision of neuropsychological testing service(s);
  - Evidence of professional training and expertise in the specific tests and/or assessment measures for which authorization is requested;
  - Physician and supervised psychometrician(s) adhere to the prevailing national professional and ethical standards regarding test administration, scoring and interpretation.
- A board-certified neurologist

See the following Optum coverage determination guideline for more information:

- Psychological and Neuropsychological Testing (to access this guideline, go to: Optum Provider Express > Clinical Resources > Guidelines/Policies/Manuals > Coverage Determination Guidelines)

**CLINICAL EVIDENCE**

**Attention Deficit Hyperactivity Disorder (ADHD)**

In a systematic review, Hall et al. (2016) describe the current evidence base for the use of neuropsychological continuous performance tests (CPTs) and objectively measured activity to support the diagnostic procedure and
medication management for children with attention-deficit hyperactivity disorder (ADHD). Four databases (PsycINFO, Medline, Allied and Complementary Medicine (AMED), and PsycARTICLES) were systematically searched to understand the current evidence base for (1) the use of CPTs to aid clinical assessment of ADHD; (2) the use of CPTs to aid medication management; and (3) the clinical utility of objective measures of activity in ADHD. Sixty relevant articles were identified. The search revealed six commercially available CPTs that had been reported on for their clinical use. There were mixed findings with regard to the use of CPTs to assess and manage medication, with contrasting evidence on their ability to support clinical decision-making. There was a strong evidence base for the use of objective measures of activity to aid ADHD/non-ADHD group differentiation, which appears sensitive to medication effects and would also benefit from further research on their clinical utility. The findings suggest that combining CPTs and an objective measure of activity may be particularly useful as a clinical tool and worthy of further pursuit.

Bechtel et al. (2012) evaluated whether boys with epilepsy-related ADHD and developmental ADHD share a common behavioral, pharaco-responsive, and neurofunctional pathophysiology. Seventeen boys with diagnosed combined epilepsy/ADHD, 15 boys with developmental ADHD, and 15 healthy controls (aged 8-14 years) performed on working memory tasks (N-back) while brain activation was recorded using functional magnetic resonance imaging. On a behavioral level, boys with epilepsy-related ADHD as well as those with developmental ADHD performed similarly poorly on tasks with high cognitive load when compared to healthy controls. On the functional level, both patient groups showed similar reductions of activation in all relevant parts of the functional network of working memory when compared to controls. The study data showed strong similarities between epilepsy-related and developmental ADHD on the behavioral, pharaco-responsive, and neural level, favoring the view that ADHD with and without epilepsy shares a common underlying neurobehavioral pathophysiology.

**Dementia, Possible Dementia, Memory Loss, and Memory Impairment**

For memory impairment or dementia screening, a single test of global measures of function or a measure of cognitive function is usually administered along with a test of behavioral or emotional symptoms. In addition to brief screening tests, for some patients, comprehensive neuropsychological testing may be indicated to confirm a diagnosis, evaluate effects of treatment, and assist in designing rehabilitative or intervention strategies for the patient. Standardized test batteries are too long for most patients with dementia; specialized dementia batteries or an individualized test battery is usually more appropriate.

In a systematic review and meta-analysis, Belleville et al. (2017) determined the extent to which cognitive measures can predict progression from mild cognitive impairment (MCI) to Alzheimer's type dementia (AD), assessed the predictive accuracy of different cognitive domain categories, and determined whether accuracy varies as a function of age and length of follow-up. The authors systematically reviewed and meta-analyzed data from longitudinal studies reporting sensitivity and specificity values for neuropsychological tests to identify individuals with MCI who will develop AD. Twenty-eight studies met the eligibility criteria (2365 participants) and reported predictive values from 61 neuropsychological tests with a 31-month mean follow-up. Values were pooled to provide combined accuracy for 14 cognitive domains. Many domains showed very good predictive accuracy with high sensitivity and specificity values. Verbal memory measures and many language tests yielded very high predictive accuracy. Other domains (e.g., executive functions, visual memory) showed better specificity than sensitivity. Predictive accuracy was highest when combining memory measures with a small set of other domains or when relying on broad cognitive batteries. The authors concluded that neuropsychological assessment can strongly contribute to predicting dementia while individuals are still in the MCI phase. According to the authors, cognitive tests are excellent at predicting MCI individuals who will progress to dementia and should be a critical component of any toolkit intended to identify AD at the pre-dementia stage.

A definitive diagnosis of Alzheimer's disease is based on the presence of memory deficits along with deficits in at least one other aspect of cognition, and in some cases is made on neuropsychological test results alone (Talwalker, 1996). Impairment in primary (short-term) memory alone is not a useful diagnostic marker for Alzheimer's disease in the early stages. Tests of delayed recall (long-term memory) and retrieval of facts of common knowledge have been shown to be the most useful measures to distinguish normal aging and early Alzheimer's disease. Dementia due to Alzheimer's disease can be distinguished from dementia due to vascular disease by differences in pattern of memory impairment and the progressive nature of Alzheimer's disease (Costa et al., 2017). Careful interpretation of test results, taken in conjunction with medical findings, allows differentiation of Alzheimer's disease from normal memory loss due to aging, and from vascular dementia.

Pedersen et al. (2017) examined the incidence, progression, and reversion of mild cognitive impairment in patients with Parkinson disease (PD-MCI) over 5 years. A population-based cohort of patients with incident PD underwent repeated neuropsychological testing of attention, executive function, memory, and visuospatial abilities at baseline (n = 178), 1 year (n = 175), 3 years (n = 163), and 5 years (n = 150). Patients were classified as PD-MCI and diagnosed with dementia according to published criteria. Thirty-six patients (20.2%) fulfilled criteria for PD-MCI at baseline. Among those with normal cognition at baseline (n = 142), the cumulative incidence of PD-MCI was 9.9% after 1 year, 23.2% after 3 years, and 28.9% after 5 years of follow-up. Overall, 39.1% of patients with baseline or
incident PD-MCI progressed to dementia during the 5-year study period. The conversion rate to dementia was 59.1% in patients with persistent PD-MCI at 1 year vs 7.2% in those with normal cognition during the first year. A total of 27.8% of patients with baseline PD-MCI and 24.2% of those with incident PD-MCI had reverted to normal cognition at study end, but the reversion rate decreased to 9.4% in those with persistent PD-MCI at 2 consecutive visits. Compared with cognitively normal patients, PD-MCI reverts within the first 3 years of follow-up were at increased risk of subsequently developing dementia. The authors concluded that early PD-MCI, regardless of persistence or reversion to normal cognition, has prognostic value for predicting dementia in patients with PD.

Yoon et al. (2015) evaluated whether olfactory and neuropsychological tests can aid in the differentiation of dementia with Lewy bodies (DBL) from Alzheimer’s disease (AD) at the mild cognitive impairment (MCI) stage since the early differentiation of DBL from AD may be important to delay disease progression. The study included 122 MCI patients who were monitored until they developed dementia or until their condition stabilized; the follow-up period averaged 4.9 years (range: 3.9-6.2 years). Baseline olfactory function as measured with the Cross-Cultural Smell Identification (CCSI) test and neuropsychological data were compared. During the follow-up period, 32 subjects developed probable AD (MCI-AD), 18 had probable DBL (MCI-DBL), 45 did not convert to dementia (MCI-stable), and eight developed a non-AD/DBL dementia. The mean CCSI score was significantly lower than that of MCI-AD patients and MCI-stable patients. The area under the curve of the receiver operating characteristic to discriminate MCI-DBL from MCI-AD using CCSI scores was 0.84. Frontal-executive function and visuospatial ability was worse in patients with MCI-DBL, while verbal recognition memory impairment was greater in those with MCI-AD. The authors concluded that olfactory and neuropsychological tests can help predict conversion to DBL or AD in patients with MCI.

Pseudodementia, a dementia of "nonorganic" etiology, is due to profound depression and can be difficult to differentiate from true dementia. The Geriatric Depression Scale is commonly used for evaluating depression in elderly people. Prospective studies have shown increased accuracy in differentiating pseudodementia from true dementia with repeated testing 12-18 months later (Yousef, 1998). This is a vital distinction to make, as organic dementia is often progressive and is usually not reversible, while dementia associated with depression may reverse or resolve with treatment.

**Developmental Disorders**

In general, empirical data, rather than evidence from prospective studies with long-term follow-up, support the use of neuropsychological testing for developmental disorders in infants and children.

Johnson et al. (2016) explored comorbidity in intellectual disability (ID) and learning disabilities (LD) in children born extremely preterm (EP; <26+0 weeks’ gestation). A UK national cohort of 161 EP children and 153 term-born controls without neurosensory impairments was assessed at 11 years of age (the EPICure Study). Neuropsychological abilities commonly affected by EP birth were assessed using the NEPSY Developmental Neuropsychological Test. Overall, 75 (47%) EP children and 7 (4.6%) controls had ID or LD. Comorbidity in ID/LD was more common among EP children than controls (24% vs. 0%). EP children with comorbid ID/LD had significantly poorer neuropsychological abilities and curriculum-based attainment than EP children with an isolated disability or no disabilities. LD was associated with a 3 times increased risk for special educational needs (SEN). However, EP children with ID alone had poorer neuropsychological abilities and curriculum-based attainment than children with no disabilities, yet there was no increase in SEN provision among this group. The authors concluded that EP children are at high risk for comorbid intellectual and learning disabilities. According to the authors, education professionals should be aware of the complex nature of EP children’s difficulties and the need for multi-domain assessments to guide intervention.

Hartman et al. (2010) examined the motor skills and executive functions in school-age children with borderline and mild intellectual disabilities (ID). Sixty-one children aged between 7 and 12 years diagnosed with borderline ID (33 boys and 28 girls; 71 < IQ < 79) and 36 age peers with mild ID (24 boys and 12 girls; 54 < IQ < 70) were assessed. Their abilities were compared with those of 97 age- and gender-matched typically developing children. Qualitative motor skills, i.e., locomotor ability and object control, were evaluated with the Test of Gross Motor Development (TGMD-2). Executive functioning (EF), in terms of planning ability, strategic decision-making and problem solving, was gauged with the Tower of London (TOL) task. Compared with the reference group, the full ID cohort scored significantly lower on all assessments. According to the investigators, the study results support the notion that besides being impaired in qualitative motor skills, intellectually challenged children are also impaired in higher-order executive functions. The authors conclude that deficits in the two domains are interrelated, so early interventions boosting their motor and cognitive development are recommended.

**Traumatic Brain Injury**

Longitudinal and case controlled studies along with numerous case reports support the use of neuropsychological tests to assess the severity of injury and the prognosis for patients with closed head trauma, to monitor progression, and to provide measures of outcome for determining degree of recovery (Hanks et al., 2016; Carlozzi et al., 2015).
**Other Disorders**

Neuropsychological testing may have a role in the clinical management of the following medical disorders:

- Brain lesions including abscesses, tumors, and arteriovenous malformations in the brain (Pranckeviciene et al., 2017; Meskal et al., 2016; Walsh et al., 2016; Cochereau et al., 2016; Ivonne et al., 2011)
- Demyelinating disease including multiple sclerosis (von Bismarck et al., 2018; Ruet and Brochet, 2018; Vollmer et al., 2016)
- Encephalopathy (Moore et al., 2017; Burton et al., 2017; Poh and Chang, 2012)
- Epilepsy and seizure disorders (Parra-Díaz and García-Casares, 2017; Grau-López et al., 2017; Wilson et al., 2015; Filippini et al., 2016; Patrikelis et al., 2016;)
- Neurotoxin exposure (Nascimento et al., 2016)
- Stroke (Lo Buono et al., 2018; Tan et al., 2017; Zweifel-Zehnder et al., 2015; Chen et al., 2015)

**Computerized Neuropsychological Testing for Concussion**

Farnsworth et al. (2017) analyzed reliability data for computerized neurocognitive tests (CNTs) using meta-analysis and examined moderating factors that may influence reliability. Studies were included in the meta-analysis if they met all of the following criteria: used a test-retest design, involved at least 1 CNT, provided sufficient statistical data to allow for effect-size calculation, and were published in English. Two independent reviewers investigated each article to assess inclusion criteria. Eighteen studies involving 2674 participants were retained. Intraclass correlation coefficients were extracted to calculate effect sizes and determine overall reliability. Moderator analyses were conducted to evaluate the effects of the length of the test-retest interval, intraclass correlation coefficient model selection, participant demographics, and study design on reliability. Heterogeneity was evaluated using the Cochran Q statistic. The proportion of acceptable outcomes was greatest for the Axon Sports CogState Test (75%) and lowest for the Immediate Post-Concussion Assessment and Cognitive Testing (ImpACT) (25%). Moderator analyses indicated that the type of intraclass correlation coefficient model used significantly influenced effect-size estimates, accounting for 17% of the variation in reliability. The authors concluded that the Axon Sports CogState Test, which has a higher proportion of acceptable outcomes and shorter test duration relative to other CNTs, may be a reliable option; however, future studies are needed to compare the diagnostic accuracy of these instruments.

Gaudet and Weyandt (2017) conducted a systematic review of existing research investigating Immediate Post-Concussion and Cognitive Testing (ImpACT) and the prevalence of invalid baseline results including the effectiveness of ImpACT’s embedded invalidity indicators in detecting suspect effort. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed in order to systematically structure a search across four databases and analysis of studies that presented data related to the prevalence of invalid performance and/or the effectiveness of ImpACT's embedded invalidity indicators. A total of 17 studies included prevalence rates of invalid performances or examined the effectiveness of ImpACT’s invalidity indicators. Of the 17 studies, 12 included prevalence rates of invalid baseline results; and across this group of studies (after removing an outlier), the weighted prevalence rate of invalid baseline results was 6%. Four of the 17 studies examined the effectiveness of ImpACT’s embedded invalidity indicators. ImpACT’s embedded invalidity indicators correctly identified suboptimal effort in approximately 80% of individuals instructed to perform poorly and avoid detection (‘coached’) or instructed to perform poorly (‘naïve’). According to the authors, these findings raise a number of issues pertaining to the use of ImpACT. Invalid performance incidence may increase with large group versus individual administration, use in nonclinical settings, and among those with Attention Deficit-Hyperactivity Disorder or learning disability. Additionally, the older desktop version of ImpACT appears to be associated with a higher rate of invalid performances than the online version. Although ImpACT’s embedded invalidity indicators detect invalid performance at a rate of 6% on average, known group validity studies suggest that these measures miss invalid performance approximately 20% of the time when individuals purposefully underperform.

In a systematic review, Alsalheen et al. (2016) assessed the literature on the reliability of the Immediate Post-Concussion Assessment and Cognitive Testing (ImpACT). Ten studies that met the inclusion criteria were included in the review. With the exception of processing speed, all composite scores consistently exhibited poor to moderate reliability. When considering 2 time points, participants who were misclassified as experiencing a "reliable change" in any score ranged between 5% and 26% for verbal memory, 2.2% and 19.6% for visual memory, 4% and 24% for processing speed, and 4% and 23.2% for reaction time. The authors concluded that the majority of ImpACT composite scores did not consistently demonstrate good reliability. According to the authors, clinicians should be cautious when ImpACT is used as a criterion for medical clearance to return to play after concussion. Because of its widespread use in concussion-related clinical research, researchers must exercise due diligence when utilizing ImpACT to evaluate outcomes after concussion or to validate other outcome measures.

Kontos et al. (2014) performed a meta-analysis assessing the effects of sport-related concussion as measured by computerized neurocognitive tests (NCT) 1-week post injury. Thirty-seven studies involving 3960 participants between 2000 and 2011 were included. Code substitution, visual memory, processing speed, and memory tasks demonstrated negative effects for concussion. Younger adolescents had lower NCT performance than older adolescents and college aged athletes. ImpACT studies demonstrated a negative effect for concussion as did those involving contact sports.
The authors found that computerized neurocognitive testing results suggest athletes suffer impairments within one week of a concussion. Several factors such as age, type of neurocognitive test, and test administrator may lead to more pronounced impairments. The authors indicated that no single tool can or should be used to measure the effect of concussion. Instead, clinicians and researchers should adopt a comprehensive approach to assessing this injury.

Echemendia et al. (2013) critically reviewed the literature from the past 12 years regarding key issues in sports-related neuropsychological assessment of concussion. Based on the review of the literature, the authors concluded that traditional and computerized neuropsychological tests are useful in the evaluation and management of concussion. Brief cognitive evaluation tools are not substitutes for formal neuropsychological assessment. According to the authors, there is insufficient evidence to recommend the widespread routine use of baseline neuropsychological testing.

Cole et al. (2018) investigated the validity of four computerized neurocognitive assessment tools (NCATs): the ANAM4, CNS-VS, CogState, and ImPACT. Two NCATs were randomly assigned and a battery of traditional neuropsychological (NP) tests administered to 272 healthy control active duty service members and to 231 service members within 7 days of an mTBI. Analyses included correlations between NCAT and the NP test scores to investigate convergent and discriminant validity, and regression analyses to identify the unique variance in NCAT and NP scores attributed to group effect. Effect sizes (Cohen’s f2) were calculated to guide interpretation of data. Only 37 (0.6%) of the 5,655 correlations calculated between NCATs and NP tests are large. The majority of correlations are small, with no clear patterns suggestive of convergent or discriminant validity between the NCATs and NP tests. Though there are statistically significant group differences across most NCAT and NP test scores, the unique variance accounted for by group status is minimal with effect sizes indicating small to no meaningful effect. The authors concluded that although the results are not overly promising for the validity of the four NCATs investigated, traditional methods of investigating psychometric properties may not be appropriate for computerized tests.

Nakayama et al. (2014) examined the test-retest reliability of commonly implemented and emerging concussion assessment tools across a large nationally representative sample of student-athletes. The assessments were divided into mandatory (Level A measures) and optional emerging concussion measures (Level B measures). Level A measures included Immediate Post-Concussion Assessment and Cognitive Test (ImPACT), Automated Neuropsychological Assessment Metrics, and the Cogstate Computerized Cognitive Assessment Tool (CCAT, formerly named Axon). Participants (n = 4874) from the Concussion Assessment, Research, and Education Consortium completed annual baseline assessments on two or three occasions. Each assessment included measures of self-reported concussion symptoms, motor control, brief and extended neurocognitive function, reaction time, oculomotor/oculovestibular function, and quality of life. The authors concluded that this investigation noted less than optimal reliability for most common and emerging concussion assessment tools. None of the assessment tools met or exceeded the accepted threshold for clinical utility. According to the authors, the use of these tools is still necessitated by the absence of a gold standard diagnostic measure, with the ultimate goal of developing more refined and sound tools for clinical use.

Nelson et al. (2016) evaluated the reliability and validity of three computerized neurocognitive tests (CNTs): ANAM, Axon Sports/CogState Sport, and ImPACT-in a common sample. High school and collegiate athletes completed two CNTs each at baseline. Concussed (n=165) and matched non-injured control (n=166) subjects repeated testing within 24 hours and at 8, 15, and 45 days post-injury. Group differences in performance were mostly moderate to large at 24 hours and small by day 8. The sensitivity of reliable change indices (RCIs) was best at 24 hours (67.8%, 60.3%, and 47.6% with one or more significant RCIs for ImPACT, Axon, and ANAM, respectively) but diminished to near the false positive rates thereafter. Across time, the CNTs' sensitivities were highest in those athletes who became asymptomatic within 1 day before neurocognitive testing but was similar to the tests' false positive rates when including athletes who became asymptomatic several days earlier. Test-retest reliability was similar among these three CNTs and below optimal standards for clinical use on many subtests. The authors indicated that their findings suggest that the clinical utility of CNTs in the context of SRC management is maximal very soon (within 24 hours) after injury or after symptom resolution and quite limited at later time points (day 8 and beyond). According to the authors, the rapid clinical recovery course from concussion and modest stability probably jointly contribute to limited signal detection capabilities of neurocognitive tests outside a brief post-injury window.

Nakayama et al. (2014) examined the test-retest reliability of the ImPACT between baseline, 45 days, and 50 days. Eighty-five physically active college students (51 male, 34 female) volunteered for this study. Participants completed the ImPACT as well as a 15-item memory test at baseline, 45 days, and 50 days. Intraclass correlation coefficients (ICCs) were calculated for ImPACT composite scores, and change scores were calculated using reliable change indices (RCIs) and regression-based methods (RBMs) at 80% and 95% confidence intervals (CIs). The respective ICCs for baseline to day 45, day 45 to day 50, baseline to day 50, and overall were as follows: verbal memory (0.76, 0.69, 0.65, and 0.78), visual memory (0.72, 0.66, 0.60, and 0.74), visual motor (processing) speed (0.87, 0.88, 0.85, and 0.91), and reaction time (0.67, 0.81, 0.71, and 0.80). All ICCs exceeded the threshold value of 0.60 for acceptable test-retest reliability. All cases fell well within the 80% CI for both the RCI and RBM, while 1% to 5% of cases fell outside the 95% CI for the RCI and 1% for the RBM. According to the authors, the study results suggest that the
ImPACT is a reliable neurocognitive test battery at 45 and 50 days after the baseline assessment. The current findings agree with those of other reliability studies that have reported acceptable ICCs across 30-day to 1-year testing intervals, and they support the utility of the ImPACT for the multidisciplinary approach to concussion management. The authors state that when managing concussed athletes, the ImPACT should not be used as a stand-alone measure.

Hang et al. (2015) determined if computerized neurocognitive testing (Immediate Post-Concussion Assessment and Cognitive Testing [ImPACT]) in the emergency department (ED) can be used as a prognostic tool to detect young athletes at risk of having protracted concussive symptoms. This was a prospective cohort study of athletes aged 11 to 18 years who presented to an ED less than 24 hours after sustaining a sports-related concussion. ImPACT was administered in the ED, and performance was categorized as “poor” if the athlete had 3 (of 4) or greater low domain scores. Participants completed the Post-Concussion Symptom Scale (PCSS) in the ED and by phone at 1 and 2 weeks after injury. Athletes were symptomatic if their PCSS score was more than 6 in males and more than 8 in females. One hundred nine patients were enrolled; 60% and 36% remained symptomatic at 1 and 2 weeks after injury, respectively. “Poor” ImPACT performance was not particularly useful in predicting athletes with protracted symptoms. In bivariate analysis, a higher ED PCSS score was associated with protracted symptoms. The authors concluded that computerized neurocognitive testing in the ED has limited usefulness in predicting protracted symptoms. Total acute symptom burden may be a useful prognostic tool in the ED evaluation of concussed young athletes, yet further research is necessary.

Nelson et al. (2017) evaluated the reliability and validity of three computerized neurocognitive assessment tools (Automated Neuropsychological Assessment Metrics [ANAM], Defense Automated Neurobehavioral Assessment [DANA], and Immediate Post-Concussion Assessment and Cognitive Testing [ImPACT]) for assessing mild traumatic brain injury (mTBI). The study included mTBI (n=94) and matched trauma control (n=80) subjects recruited from a level I trauma center emergency department (ED) completed symptom and neurocognitive assessments within 72 hours of injury and at 15 and 45 days post-injury. Concussion symptoms were also assessed via phone at 8 days post-injury. Computerized neurocognitive assessment tools (CNTs) did not differentiate between groups at any time point. Roughly a quarter of stability coefficients were over .70 across measures and test-retest intervals in controls. The authors concluded that the CNTs evaluated, developed and widely used to assess sport-related concussion, did not yield significant differences between patients with mTBI versus other injuries. Symptom scores better differentiated groups than CNTs, with effect sizes weaker than those reported in sport-related concussion studies. According to the authors, nonspecific injury factors, and other characteristics common in ED settings, likely affect CNT performance across trauma patients as a whole and thereby diminish the validity of CNTs for assessing mTBI in this patient population. The authors indicated that this investigation had several limitations. First, subjects were evaluated in a laboratory setting within 72 hr of injury; thus, it is possible that stronger group differences in clinical assessment measures would have been found had subjects been assessed more acutely (such as within the ED). Second, the study design (i.e., assignment of two of three CNTs to each subject) and presence of loss to follow-up (16% at 45 days post-injury) contributed to smaller sample sizes (<50) for some CNT measures and at some time points.

Cole et al. (2017) investigated the validity of four computerized neurocognitive assessment tools (NCATs): the ANAM4, CNS-VS, CogState, and ImPACT. Two NCATs were randomly assigned and a battery of traditional neuropsychological (NP) tests administered to healthy control active duty service members (n = 272) and to service members within 7 days of an mTBI (n = 231). Analyses included correlations between NCAT and the NP test scores to investigate convergent and discriminant validity, and regression analyses to identify the unique variance in NCAT and NP scores attributed to group status. Effect sizes (Cohen's f2) were calculated to guide interpretation of data. Only 37 (0.6%) of the 5,655 correlations calculated between NCATs and NP tests are large. The majority of correlations are small, with no clear patterns suggestive of convergent or discriminant validity between the NCATs and NP tests. Though there are statistically significant group differences across most NCAT and NP test scores, the unique variance accounted for by group status is minimal (i.e., semipartial R2 ≤ 0.033, 0.024, 0.062, and 0.011 for ANAM4, CNS-VS, CogState, and ImPACT, respectively), with effect sizes indicating small to no meaningful effect. The authors concluded that though the results are not overly promising for the validity of the four NCATs investigated, traditional methods of investigating psychometric properties may not be appropriate for computerized tests.

In a consensus statement, the 5th International Conference on Concussion in Sport states that the use of neuropsychological testing (NP) contributes significant information in concussion assessment. Brief computerized cognitive evaluation tools are a commonly utilized component of these assessments worldwide given the logistical limitation in accessing trained neuropsychologists. However, it should be noted that these are not substitutes for complete NP assessment. For children, it is recommended that age-specific validated symptom-rating scales be used in sport-related concussion (SRC) assessment, and further research is required to establish the role and utility of computerized NP testing in this age group. The consensus statement suggests that baseline testing may be useful, but is not necessary for interpreting post-injury scores (McCroriet et al., 2017).
Baseline Neuropsychological Testing for Concussion

In a retrospective, cross-sectional study, Abeare et al. (2018) assessed the prevalence of invalid performance on baseline testing and assessed whether the prevalence varies as a function of age and validity indicator. Participants included 7897 consecutively tested equivalently proportioned male and female athletes aged 10 to 21 years, who completed baseline neurocognitive testing for the purpose of concussion management. Baseline assessment was conducted with the Immediate Postconcussion Assessment and Cognitive Testing (ImPACT). Base rates of failure on published ImPACT validity indicators were compared within and across age groups. Hypotheses were developed after data collection but prior to analyses. Of the 7897 study participants, 4086 (51.7%) were male, mean (SD) age was 14.71 years, 7820 (99.0%) were primarily English speaking, and the mean (SD) educational level was 8.79 years. The base rate of failure ranged from 6.4% to 47.6% across individual indicators. Most of the sample (55.7%) failed at least 1 of 4 validity indicators. The base rate of failure varied considerably across age groups (117 of 140 [83.6%] for those aged 10 years to 14 of 48 [29.2%] for those aged 21 years), representing a risk ratio of 2.86. The authors indicated that the results for base rate of failure were surprisingly high overall and varied widely depending on the specific validity indicator and the age of the examinee. The strong age association, with 3 of 4 participants aged 10 to 12 years failing validity indicators, suggests that the clinical interpretation and utility of baseline testing in this age group is questionable. According to the authors, these findings underscore the need for close scrutiny of performance validity indicators on baseline testing across age groups.

Nelson et al. (2015) examined the rates and predictors of invalid baseline performance for 3 computerized neuropsychological tests (CNTs): Automated Neuropsychological Assessment Metrics (ANAM), Axon Sports, and Immediate Post-Concussion and Cognitive Testing (ImPACT). High school and collegiate athletes (N = 2063) completed 2 of 3 CNTs each during preseason evaluations. All possible pairings were present across the sample, and the order of administration was randomized. Examiners provided 1-on-1, scripted pretest instructions, emphasizing the importance of good effort. Profile validity was determined by the manufacturers’ standard criteria. The overall percentage of tests flagged as of questionable validity was lowest for ImPACT (2.7%) and higher for ANAM and Axon (10.7% and 11.3%, respectively). The majority of invalid baseline profiles were flagged as such because of failure on only 1 validity criterion. Several athlete and testing factors (eg, attention deficit hyperactivity disorder [ADHD], estimated general intellectual ability, administration order) predicted validity status for 1 or more CNTs. Considering only first CNT administrations and participants without ADHD and/or a learning disability (n = 1835) brought the rates of invalid baseline performances to 2.1%, 8.8%, and 7.0% for ImPACT, ANAM, and Axon, respectively. Invalid profiles on the Medical Symptom Validity Test (MSVT) were rare (1.8% of participants) and demonstrated poor correspondence to CNT validity outcomes. The investigators concluded that the validity criteria for these CNTs may not identify the same causes of invalidity or be equally sensitive to effort. According to the investigators, the validity indicators may not be equally appropriate for some athletes (e.g., those with neurodevelopmental disorders).

MacDonald and Duerson (2015) examined the test-retest reliability of a computerized neurocognitive test used for baseline assessments in high school athletes over 1 year. Study participants included high school athletes (N = 117) participating in American football or soccer. All study participants completed 2 baseline computerized neurocognitive tests taken 1 year apart at their respective schools. The test measures performance on 4 cognitive tasks: identification speed (Attention), detection speed (Processing Speed), one card learning accuracy (Learning), and one back speed (Working Memory). Reliability was assessed by measuring the intraclass correlation coefficient (ICC) between the repeated measures of the 4 cognitive tasks. Pearson and Spearman correlation coefficients were calculated as a secondary outcome measure. The measure for identification speed performed best and the measure for one card learning accuracy performed worst. All tests had marginal or low reliability. The authors concluded that in a population of high school athletes, computerized neurocognitive testing performed in a community setting demonstrated low to marginal test-retest reliability on baseline assessments 1 year apart. The authors stated that further investigation should focus on (1) improving the reliability of individual tasks tested, (2) controlling for external factors that might affect test performance, and (3) identifying the ideal time interval to repeat baseline testing in high school athletes. According to the authors, this study adds to the evidence that suggests in this population baseline testing may lack sufficient reliability to support clinical decision making.

Computerized Cognitive Testing such as Mindstreams and BrainCare

Shopin et al. (2013) compared a computerized battery of neuropsychological tests for memory, attention and executive functions (MindStreams) with the Montreal Cognitive Assessment (MoCA) to detect mild-to-moderate cognitive impairments in poststroke patients. A total of 454 patients with transient ischemic attack (TIA) or stroke enrolled to the TABASCO (Tel Aviv Brain Acute Stroke Cohort) study, a prospective study which includes consecutive first-ever mild-to-moderate stroke patients, were included. All participants underwent neurological and cognitive evaluations. The patients’ mean MoCA and MindStreams scores were lower than normal; however, the TIA group presented significantly better scores using either method. The correlation between the MoCA and the computerized global score was 0.6. A significant correlation was found between the subcategory scores (executive function, memory and attention). However, the MoCA identified many more subjects with low scores (<26) compared to the MindStreams (70.6 vs. 15.7%).
Punchik et al. (2015) retrospectively analyzed patients referred to a comprehensive geriatric assessment unit with screening instruments to determine if further comprehensive cognitive assessment was necessary. Cognitive screening and assessment included visual-spatial components: the Mini Mental State Examination, the Clock Drawing Test, the Montreal Cognitive Assessment Test, and the Neurotrax (Mindstreams) computerized cognitive assessment battery. The average age of the 190 eligible patients was 81.09±5.42 years. Comparing the individual tests with that of the visual-spatial index of Neurotrax, the investigators found the Trail Making B test to be most sensitive (72.4%) and the Cube Test to have the highest specificity (72.8%). A combination of tests resulted in higher sensitivity and lower specificity. The authors concluded that the use of a combination of visual-spatial tests for screening in neurocognitive disorders should be evaluated in further prospective studies.

Dwolatzky et al. (2010) examined the validity of the Mindstreams battery designed specifically for evaluating those with moderate cognitive impairment. One hundred and seventy participants over the age of 60 years performed the computerized battery in addition to standard clinical evaluation. Staging was according to the Clinical Dementia Rating Scale (CDR) on the basis of clinical data but independent of computerized cognitive testing results, thus serving as the gold standard for evaluating the discriminant validity of the computerized measures. Seven participants received a global Clinical Dementia Rating (CDR) score of 0 (not impaired), 76 were staged as CDR 0.5 (very mildly impaired), 58 as CDR 1 (mildly impaired), 26 as CDR 2 (moderately impaired), and 3 as CDR 3 (severely impaired). Mindstreams Global Score performance was significantly different across CDR groups, reflecting poorer overall battery performance for those with greater impairment. This was also true for the domain summary scores, with Executive Function and Memory distinguishing best between CDR 0.5 and 1, and Orientation best differentiating among CDR 1 and 2. The investigators concluded that the Mindstreams battery for moderate impairment differentiates among varying degrees of cognitive impairment in older adults, providing detailed and distinct cognitive profiles. Limitations of this study include lack of a control group and small sample size.

Achiron et al. (2007) compared the Mindstreams test battery with the Neuropsychological Screening Battery for Multiple Sclerosis (NSBMS), which is considered the reference standard for cognitive screening in MS, in patients with MS (n=58) and in a control group of healthy volunteers (n=71) who were matched for age, education, gender, handedness, and computer use. The 71 controls were randomly selected from 410 individuals who were used to establish normative values for the Mindstreams system. Five of the 7 index scores (memory, executive function, attention, information processing, and motor skills) significantly discriminated MS patients from controls, while visuospatial and verbal-function indexes did not. However, the NSBMS system was not assessed in a similar manner; only correlation coefficients of the Mindstreams index scores and NSBMS system outcomes were presented. As with the study by Ritsner et al. (2006), all of the correlations were statistically significant, but the magnitude of the correlation coefficients indicates only moderate correlation at best. This study, therefore, demonstrates the capability of the Mindstreams system to differentiate MS patients from healthy volunteers across 5 of 7 cognitive domains, but the data are insufficient to establish the equivalence of the Mindstreams system to the standard of care or to demonstrate a benefit of Mindstreams assessment on clinical outcomes.

Racine et al. (2016) conducted a study that included 469 late middle-aged participants from the Wisconsin Registry for Alzheimer's Prevention (mean age 63.8±7 years at testing; 67% female; 39% APOE4+) to evaluate whether computerized cognitive assessments, like the CogState battery, are sensitive to preclinical cognitive changes or pathology in people at risk for Alzheimer's disease (AD). The study examined relationships between a CogState abbreviated battery (CAB) of seven tests and demographic characteristics, traditional paper-based neuropsychological tests as well as a composite cognitive impairment index, cognitive impairment status (determined by consensus review), and biomarkers for amyloid and tau (CSF phosphorylated-tau/Aβ42 and global PET-PiB burden) and neural injury (CSF neurofilament light protein). CSF and PET-PiB were collected in n=71 and n=91 participants, respectively, approximately four years prior to CAB testing. For comparison, three traditional tests of delayed memory in parallel were examined. Similar to studies in older samples, the CAB was less influenced by demographic factors than traditional tests. CAB tests were generally correlated with most paper-based cognitive tests examined and mapped onto the same cognitive domains. Greater composite cognitive impairment index was associated with worse performance on all CAB tests. Cognitively impaired participants performed significantly worse compared to normal controls on all but one CAB test. Poorer One Card Learning test performance was associated with higher levels of CSF phosphorylated-tau/Aβ42. The authors concluded that these results support the use of the CogState battery as measures of early cognitive impairment in studies of people at risk for Alzheimer's disease. However, according to the authors, the study also suggests that CogState at a single time point may not substantially improve preclinical AD detection over traditional neuropsychological tests.

Overall, the available evidence is insufficient to establish the validity of computerized cognitive testing such as Mindstreams and BrainCare compared with traditional tests for the assessment of cognitive impairment.

**Intermittent Explosive Disorder**

There are no clear underlying medical issues associated with intermittent explosive disorder, nor are there published clinical trials that support the use of neuropsychological testing for this disorder. According to the Diagnostic and Neuropsychological Testing Under the Medical Benefit
UnitedHealthcare Commercial Medical Policy

Proprietary Information of UnitedHealthcare. Copyright 2018 United HealthCare Services, Inc.
Neuropsychological Testing Under the Medical Benefit

Cognitive function tests were utilized at baseline and at three time points after surgery (3 weeks, 4 months, 1 year) following coronary intervention (PCI), and neuropsychological data were gathered from 46 healthy controls, 42 cardiac patients referred for percutaneous coronary intervention, and 43 cardiac patients referred for coronary artery bypass grafting (CABG). 

Mental State Examination were computed. From 593 citations identified, 8 publications met inclusion criteria. Risk of bias included selective HF patient samples, and no study examined the diagnostic test accuracy of the cognitive screening instruments in this population.

In a systematic review, Cameron et al. (2016) evaluated three neuropsychological tests (Trail Making Test (TMT), Go/Nogo Task and Stroop Task) that were completed by four headache patient samples (chronic CH, episodic CH in the active or inactive period, and migraine patients) and compared to healthy controls. Analyses revealed that patients with chronic and active episodic CH appeared particularly impaired in tests relying more on intact executive functioning (EF) than on basal cognitive processes. Within the CH groups performance decreased linearly with increasing severity. The authors stated that impaired EF could also result from medication and sleep disturbances due to active CH. The authors went on to say that because decreased performance was also present outside the attacks it may hint at generally altered brain function, but does not necessarily reflect clinically relevant behavior.

There is insufficient clinical evidence to conclude that the use of neuropsychological testing for patients with migraine headaches without associated cognitive disorders can be used effectively for clinical decision making to improve management of this condition. No published clinical trials were found that support the use of neuropsychological testing for clinical decision making to improve management for patients with other types of headaches who did not have associated cognitive disorders.

**History of Myocardial Infarction**

Literature addressing the neuropsychological consequences of myocardial infarction is not conclusive. Studies on the relationship between myocardial infarction and cognitive functioning have demonstrated conflicting results. Some studies show a detrimental effect of myocardial infarction on cognitive skills and other studies have shown no difference in cognitive skills for patients with migraine headaches (Foti et al., 2017).

Dresler et al. (2012) evaluated three neuropsychological tests (Trail Making Test (TMT), Go/Nogo Task and Stroop Task) that were completed by four headache patient samples (chronic CH, episodic CH in the active or inactive period, and migraine patients) and compared to healthy controls. Analyses revealed that patients with chronic and active episodic CH appeared particularly impaired in tests relying more on intact executive functioning (EF) than on basal cognitive processes. Within the CH groups performance decreased linearly with increasing severity. The authors stated that impaired EF could also result from medication and sleep disturbances due to active CH. The authors went on to say that because decreased performance was also present outside the attacks it may hint at generally altered brain function, but does not necessarily reflect clinically relevant behavior.

There is insufficient clinical evidence to conclude that the use of neuropsychological testing for patients with migraine headaches without associated cognitive disorders can be used effectively for clinical decision making to improve management of this condition. No published clinical trials were found that support the use of neuropsychological testing for clinical decision making to improve management for patients with other types of headaches who did not have associated cognitive disorders.

**Headdches Including Migraine**

Literature addressing the neuropsychological consequences of migraine headaches is not conclusive. Studies on the relationship between migraine and cognitive functioning have demonstrated conflicting results. Some studies show a detrimental effect of migraine on cognitive skills and other studies have shown no difference in cognitive skills for patients with migraine headaches (Foti et al., 2017).

In a systematic review, Cameron et al. (2016) evaluated the diagnostic accuracy of cognitive screening instruments in screening for mild cognitive impairment (MCI) in heart failure (HF) patients. Inclusion criteria for the review were as follows: primary studies examining cognitive impairment in HF, administration of a cognitive screening instrument and neuropsychological test battery, and cognitive impairment indicated by performance on neuropsychological tests 1.5 SDs less than that of normative data. The precision, accuracy, and receiver operating characteristic curves of the Mini Mental State Examination were computed. From 593 citations identified, 8 publications met inclusion criteria. Risk of bias included selective HF patient samples, and no study examined the diagnostic test accuracy of the cognitive screening instruments. The Mini Mental State Examination had low sensitivity (26%) and high specificity (95%) with a score of 28 or less as the optimal threshold for MCI screening. The authors concluded that screening for cognitive impairment in HF is recommended; however, future studies need to establish the diagnostic accuracy of screening instruments of MCI in this population.

Neuropsychological data were gathered from 46 healthy controls, 42 cardiac patients referred for percutaneous coronary intervention (PCI), and 43 cardiac patients referred for coronary artery bypass grafting (CABG). Fourteen cognitive function tests were utilized at baseline and at three time points after surgery (3 weeks, 4 months, 1 year).
No clear pattern of group differences or change at follow-up emerged. A greater percentage of CABG patients than controls worsened in seven tests (three at 1 year), but a greater percentage of PCI patients than controls also worsened in seven tests (three at 1 year). Generalized estimating equations showed only two tests (Wechsler Adult Intelligence Scale, Third Edition, Digit Symbol, and Hopkins Verbal Learning Test, Revised, Total Recall) to be significantly different between groups from baseline to 1 year. Compared with healthy controls, more PCI patients than CABG patients worsened in the former of those two tests, whereas more PCI and CABG patients improved on the latter. The investigators concluded that current CABG procedure does not appear to create cognitive decline (Sweet, 2008).

There is insufficient clinical evidence to conclude that the use of neuropsychological testing for patients with myocardial infarction without associated cognitive disorders can be used effectively for clinical decision making to improve management of this condition.

### Professional Societies

#### American Academy of Neurology (AAN)

In an evidence-based guideline update for the evaluation and management of concussion in sports, the AAN states that it is likely that neuropsychological testing of memory performance, reaction time, and speed of cognitive processing, regardless of whether administered by paper-and-pencil or computerized method, is useful in identifying the presence of concussion (sensitivity 71%–88% of athletes with concussion). This is based on evidence from 1 Class II study and multiple Class III studies. The AAN also states that both types of testing (paper-and-pencil or computerized) generally require a neuropsychologist for accurate interpretation, although the tests may be administered by a non-neuropsychologist. According to AAN, there is insufficient evidence to support conclusions about the use of neuropsychological testing in identifying concussion in preadolescent age groups. The AAN goes on to say that inexperienced licensed health care providers (LHCPs) should be instructed in the proper administration of standardized validated sideline assessment tools. This instruction should emphasize that these tools are only an adjunct to the evaluation of the athlete with suspected concussion and cannot be used alone to diagnose concussion (Level B – probably effective). The AAN further states that LHCPs caring for athletes might utilize individual baseline scores on concussion assessment tools, especially in younger athletes, those with prior concussions, or those with preexisting learning disabilities/attention deficit/hyperactivity disorder, as doing so fosters better interpretation of postinjury scores (Level C - Possibly effective) (Giza et al., 2013).

The AAN published a report regarding neuropsychological testing of adults. This report indicates that neuropsychological testing is most useful for management planning in patients with suspected dementia, multiple sclerosis, Parkinson's disease, traumatic brain injury, stroke, and HIV encephalopathy. It is also useful for detecting deficits in patients with particularly high premorbid intelligence levels in which bedside-type clinical testing may be insensitive to mild alterations. Neuropsychological testing also has an important role in evaluating patients undergoing epilepsy surgery (Assessment: neuropsychological testing of adults. Considerations for neurologists. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 1996).

In a practice guideline update summary for mild cognitive impairment (MCI), the AAN recommends that when performing a Medicare Annual Wellness Visit, clinicians should not rely on historical report of subjective memory concerns alone when assessing for cognitive impairment (Level B). Various assessment instruments have acceptable diagnostic accuracy for detecting MCI, with no instrument being superior to another. The guideline states that because brief cognitive assessment instruments are usually calibrated to maximize sensitivity rather than specificity, patients who test positive for MCI should then have further assessment (e.g., more in-depth cognitive testing, such as neuropsychological testing with interpretation based on appropriate normative data) to formally assess for this diagnosis (Petersen et al., 2018).

A practice parameter for the screening and diagnosis of autism developed by the American Academy of Neurology and the Child Neurology Society indicates that neuropsychological, behavioral, and academic assessments should be performed as needed, in addition to the cognitive assessment, to include social skills and relationships, educational functioning, problematic behaviors, learning style, motivation and reinforcement, sensory functioning, and self-regulation for the diagnosis of autism (Filipek et al., 2000).

#### American Heart Association and the American Stroke Association

In a guideline for Healthcare Professionals from the American Heart Association and the American Stroke Association, Winn et al. (2016) provided a synopsis of best clinical practices in the rehabilitative care of adults recovering from stroke. According to the guideline, a formal neuropsychological examination (including assessment of language, neglect, praxis, memory, emotional responses, and specific cognitive syndromes) may be helpful after the detection of cognitive impairment with a screening instrument. Neuropsychological protocols must be sensitive to a wide range of abilities, especially the assessment of executive and attentional functions. These guidelines state that screening for cognitive deficits is recommended for all stroke patients before discharge home (class I, level B evidence). The

---

**Neuropsychological Testing Under the Medical Benefit**

UnitedHealthcare Commercial Medical Policy

Proprietary Information of UnitedHealthcare. Copyright 2018 United HealthCare Services, Inc.
Neuropsychological testing under the medical benefit (class Iia, level C evidence).

**American Psychological Association (APA)**

The American Psychological Association published updated guidelines for the evaluation of dementia and age-related cognitive change. The guidelines include the following information regarding neuropsychological testing for this condition (American Psychological Association, 2012):

- Neuropsychological evaluation and cognitive testing remain among the most effective differential diagnostic methods in discriminating pathophysiological dementia from age-related cognitive decline, cognitive difficulties that are depression-related, and other related disorders. Even after reliable biological markers have been discovered, neuropsychological evaluation and cognitive testing will still be necessary to determine the onset of dementia, the functional expression of the disease process, the rate of decline, the functional capacities of the individual, and hopefully, response to therapies.
- Comprehensive neuropsychological evaluations for dementia and cognitive change include tests of multiple cognitive domains, typically including memory, attention, perceptual and motor skills, language, visuospatial abilities, reasoning, and executive functions. Measures of mood and personality may be relevant in many cases. Psychologists are encouraged to refer to current compendia resources and the clinical research literature in selecting assessment instruments. Psychologists are encouraged to use standardized, reliable, and valid tests.
- Technology assisted assessments (e.g., computer administered cognitive batteries, tele-health visits) are rapidly advancing but appropriate psychometric properties and normative data are nascent. These technologies may have significant advantages for older persons with limited mobility or health-care access, but may also disadvantage older persons with limited experience and expertise interacting with technology.

**American Psychiatric Association**

In its guidelines on the treatment of Alzheimer's disease and other dementias, the American Psychiatric Association states that neuropsychological testing may be helpful in deciding whether a patient with subtle or atypical symptoms actually has dementia. Neuropsychological testing is particularly useful in the evaluation of individuals who present with mild cognitive impairment, which requires evidence of memory and/or other cognitive difficulties in the presence of intact functioning, and in the evaluation of individuals with the onset of dementia early in life. Testing may help to characterize the extent of cognitive impairment, to distinguish among the types of dementias, and to establish baseline cognitive function. The American Psychiatric Association also states that a variety of research definitions for mild cognitive impairment are in place, but there is no consensus on the optimal definition. The most widely accepted definition requires the following (American Psychiatric Association, 2007):

- Subjective cognitive complaints,
- Evidence of objective deficits in cognitive function based on age- and education-adjusted norms on standardized neuropsychological tests,
- Intact daily functioning,
- Evidence of cognitive decline from a prior level, and
- Evidence of not meeting the criteria for dementia.

**American Academy of Pediatrics (AAP)**

A joint statement for learning disabilities, dyslexia, and vision from the American Academy of Pediatrics, Section on Ophthalmology, Council on Children with Disabilities; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; and the American Association of Certified Orthoptists states that children who exhibit signs of learning disabilities should be referred for educational, psychological, neuropsychological, and/or medical diagnostic assessments (AAP, 2009; Reaffirmed 2014).

In a policy statement on sport-related concussion in children and adolescents, the AAP states that neuropsychological testing can be helpful to provide objective data to athletes and their families after a concussion. Neuropsychological testing is one tool in the complete management of a sport-related concussion and alone does not make a diagnosis or determine when return to play is appropriate. According to the AAP, testing is performed by using one of several computerized neuropsychological tests including ANAM (Automated Neuropsychological Assessment Metrics), CogState, HeadMinder, and ImPACT or through pencil-and-paper testing administered by a neuropsychologist. Each of the computerized tests has published data on test-retest reliability, and all have demonstrated deficits in concussed athletes compared with their baseline assessments. One critique of the computerized tests is that the vast majority of studies have been conducted by the developers of the tests, which raises some concern for bias, because some independent study results have suggested slightly less reliable results. More rigorous pencil-and-paper testing conducted formally by a neuropsychologist is also an option, although test-retest reliability has been questioned. If an athlete is suffering from postconcussive symptoms over several months or has had multiple concussions, formal assessment by a neuropsychologist may be beneficial, specifically to identify areas for which the athlete may need academic accommodations (Halstead and Walter, 2010; Reaffirmed August 2014).
American Academy of Child and Adolescent Psychiatry (AACAP)

Practice parameters from the American Academy of Child and Adolescent Psychiatry (Volkmar et al., 2014) state that neuropsychological correlates of autism spectrum disorder include impairments in executive functioning (e.g., simultaneously engaging in multiple tasks) (Ozonoff et al., 1991), weak central coherence (integrating information into meaningful wholes) (Happe and Frith, 2006), and deficits in theory-of-mind tasks (taking the perspective of another person) (Baron-Cohen et al., 1985).

National Academy of Neuropsychology (NAN)

The National Academy of Neuropsychology developed an education paper to provide information to clinicians, healthcare administrators, and policy developers about the purpose, strengths, and limitations of computerized cognitive screening tests versus comprehensive neuropsychological evaluations. Screening tests are generally brief and narrow in scope, they can be administered during a routine clinical visit, and they can be helpful for identifying individuals in need of more comprehensive assessment. Some screening tests can also be helpful for monitoring treatment outcomes. Comprehensive neuropsychological assessments are multidimensional in nature and used for purposes such as identifying primary and secondary diagnoses, determining the nature and severity of a person's cognitive difficulties, determining functional limitations, and planning treatment and rehabilitation. Cognitive screening tests are expected to play an increasingly important role in identifying individuals with cognitive impairment and in determining which individuals should be referred for further neuropsychological assessment. However, limitations of existing cognitive screening tests are present and cognitive screening tests should not be used as a replacement for comprehensive neuropsychological testing (Roebuck-Spencer et al, 2017).

In a policy for the evaluation of childhood learning disorders, the NAN states that when comprehensive information about a child's brain-related strengths and weaknesses is necessary to understand potential sources of the problem and implications for functioning, a neuropsychological evaluation is most often the best choice (Silver et al., 2006).

In a position paper on the diagnosis and management of sports-related concussion, the NAN states that neuropsychological evaluation is recommended for the diagnosis, treatment, and management of sports-related concussion at all levels of play (Moser et al., 2007).

American Academy of Clinical Neuropsychology (AACN) and National Academy of Neuropsychology (NAN)

A joint position paper of the AACN and NAN sets forth their position on appropriate standards and conventions for computerized neuropsychological assessment devices (CNADs). The authors state that CNADs are subject to, and should meet, the same standards for the development and use of educational, psychological, and neuropsychological tests (American Psychological Association, 1999) as are applied to examiner-administered tests. The authors also state that those employing CNADs have the education, training, and experience necessary to interpret their results in a manner that will best meet the needs of the patients they serve (Bauer et al., 2012).

U.S. FOOD AND DRUG ADMINISTRATION (FDA)

In June 2015, the FDA cleared Cognivue through the de novo classification pathway. The de novo pathway is used for low- to moderate-risk medical devices that are not equivalent to an already legally marketed device. FDA identifies Cognivue as a “Computerized Cognitive Assessment Aid.” According to the FDA, this test is indicated as an adjunctive tool for evaluating perceptual and memory function in individuals aged 55 to 95 years old. See the following website for more information: https://www.accessdata.fda.gov/cdrh_docs/pdf13/DEN130033.pdf. (Accessed April 6, 2018)

On August 22, 2016, the FDA began to allow the marketing of two computerized neurocognitive tests for assessing individuals immediately following a suspected brain injury or concussion: ImPACT and ImPACT Pediatric (ImPACT Applications). Both tests were reviewed via the agency’s de novo classification process, a pathway to market for certain “first-of-a-kind” and low- to-moderate-risk medical devices. ImPACT and ImPACT Pediatric are computerized cognitive assessment aids intended for use in conjunction with standard medical evaluation for signs and symptoms of a head injury. ImPACT is designed to assess people 12 to 59 years of age, while ImPACT Pediatric is designed for children aged 5 to 11 years. The FDA states that these tests should not be used to “rule out a concussion or determine whether an injured player should return to a game.” See the following websites for more information:

- http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm517526.htm

(Accessed April 6, 2018)
Medicare does not have a National Coverage Determination (NCD) for neuropsychological testing. Local Coverage Determinations (LCDs) exist; see the LCDs for Outpatient Psychiatry and Psychology Services, Psychiatry and Psychology Services, Psychological and Neuropsychological Testing, Partial Hospitalization Programs, Psychiatric Codes, Psychiatric Partial Hospitalization Programs and Therapy and Rehabilitation Services. (Accessed April 20, 2018)

REFERENCES


<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
</table>
| 06/01/2018 | • Updated coverage rationale:  
  o Replaced language indicating:  
    ▪ "[The listed service] is proven and medically necessary" with "[the listed service] is proven and/or medically necessary"  
    ▪ "[The listed services] are unproven and not medically necessary" with "[the listed services] are unproven and/or not medically necessary"  
  o Replaced reference(s) to:  
    ▪ "Patient" with "individual"  
    ▪ "Persons" with "individuals"  
  • Updated supporting information to reflect the most current description of services, clinical evidence, FDA and CMS information, and references  
  • Archived previous policy version 2017T0152O |